Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
about
Treatment of juvenile idiopathic arthritis: a revolution in careThe Future Is Now: Biologics for Non-Infectious Pediatric Anterior UveitisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentAn intra-articular ganglion cyst in a patient with juvenile idiopathic arthritisA survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunitiesWhat are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritisDo inflammatory bowel disease therapies cause cancer?Validity of juvenile idiopathic arthritis diagnoses using administrative health data.Evolution of Pediatric Chronic Disease Treatment Decisions: A Qualitative, Longitudinal View of Parents' Decision-Making ProcessAssociation between drug intake and incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a nested case-control study.Malignancy incidence in 5294 patients with juvenile arthritisTreatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?Complexity and Specificity of the Neutrophil Transcriptomes in Juvenile Idiopathic Arthritis.Update on the treatment of juvenile idiopathic arthritisTumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseasesAnalysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patientsParents' information needs and influential factors when making decisions about TNF-α inhibitors.Using registries to identify adverse events in rheumatic diseases.The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritisDisease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanerceptRole of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.Adding to complexity: comorbidity in paediatric rheumatic disease.Update on biologicals for treatment of juvenile idiopathic arthritis.What is the background incidence of malignancy in children with rheumatic disease?Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum.Canakinumab in pediatric rheumatic diseases.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Challenges and approaches for the development of safer immunomodulatory biologics.Diagnosis and treatment of pediatric psoriasis: current and future.Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.Anaplastic large cell lymphoma in a patient with systemic onset juvenile arthritis: case report and review of literature.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.Long-term safety of immunomodulators in pediatric inflammatory diseases.Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.Novel treatment options for juvenile idiopathic arthritis.
P2860
Q26849497-63D87FC1-24E0-4E33-B7C0-E77E62116717Q27025862-38338EAD-FCC9-4893-B277-9B65502E7C70Q28079246-56ACFE98-FFA5-4A2D-AE52-23F0BC2D3C46Q33574864-175960A2-882B-44FC-A52F-1DD6BBE5948EQ33576975-A34C0F3E-4A73-4E48-8E7B-BC71540A5024Q33765738-278FFBF6-9C1E-4C5F-99DB-B6FA3A0B9B60Q34169257-C340AAF9-D917-4153-862E-A3A38287515EQ34613890-F08103AA-37F8-4105-B96E-DA0D98969AE5Q35290573-0A58DC8F-E7D1-424D-A7C4-0161370690A9Q36200559-22A4267F-C349-4616-8F5D-3F6208D7A566Q36538046-279D1A08-4B54-42F5-892D-0573FA40F050Q36882839-9D254D57-F5EC-4E13-8940-88EBA3E474A1Q36909288-71DE238D-00EC-43F0-8296-0B9A0A237FFCQ36964382-315474C9-2A87-41F6-8758-5FB6B4403984Q36974508-87506FBE-25ED-48DE-9FC8-D8E5DD20DBB9Q37060351-49495F32-AA9A-48F5-9550-5151BF17D4CCQ37186231-4F37283A-50F9-4762-8F02-89B7E51E61DEQ37233437-C2C2CD50-1957-41D4-9AB0-2B2CE5153DA2Q37258029-0BB97900-E7D7-4D0D-A9CD-AD2C6BB08085Q37268816-08B6066F-49AE-43FF-8A05-D09B2C8FE5BAQ37274470-380FE381-9A68-4EA0-9931-F5595D68F3FEQ37356217-783DB4DE-2485-4B86-8ACC-F13DF9600A82Q37518319-9AF45F8D-1BDF-4189-8530-07225369B897Q37561994-99C9C767-E51A-4E3B-99C1-EDC68FD25698Q38048234-B8B2DE53-C253-4994-B940-2462DD44A20FQ38071693-546D2066-CD3A-4D6B-80AC-15B500EAEEF9Q38078882-4D2AD13E-56B0-46AB-A8D1-03900D2D917AQ38079831-B4EAFA92-59E7-4EE9-9814-91E343DC0FF2Q38085662-1D811DCD-88CF-49BC-BC79-F4347F1F025AQ38092899-D89309D7-C741-41FF-BB7F-37675E0D55A5Q38093772-AE41FE38-C72D-4A55-9DA9-B667D1180BBCQ38107168-826400F9-884E-4EC4-93CF-07FB6F670E22Q38144094-22B291A0-47F5-4A9E-B5AC-950DFB302C56Q38201855-4E67E11C-6588-41AC-8DAF-91DCB754B63CQ38203622-05B4E469-E0E7-46FD-B13D-2F300D1647ECQ38214382-C0E4AA63-0791-43FB-956F-294443AE9B5EQ38232338-EE730935-307B-49A7-9977-F883496064F3Q38406386-B3AD0D8E-5CEE-4314-9198-19954DA30B98Q38530469-A58B6FCE-A732-444A-9586-E6D3ACD717C9Q38570721-3170221E-F7ED-4CBA-851E-CD8A0D2D0DE7
P2860
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
@ast
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
@en
type
label
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
@ast
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
@en
prefLabel
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
@ast
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
@en
P2093
P2860
P356
P1476
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
@en
P2093
Christina J Bemrich-Stolz
Daniel H Solomon
Elizabeth Delzell
Fenglong Xie
James D Lewis
Jeffrey R Curtis
Kenneth G Saag
Kevin Haynes
Safety Assessment of Biological Therapeutics Collaboration
P2860
P304
P356
10.1002/ART.34348
P577
2012-02-10T00:00:00Z